Pair Name	Beta-Elemene, Cetuximab
Disease Info	[ICD-11: 2B91]	Colorectal cancer		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	CDH2	hsa1000
	Down-regulation	Expression	FTH1	hsa2495
	Down-regulation	Expression	GLS	hsa2744
	Down-regulation	Expression	GPX4	hsa2879
	Up-regulation	Expression	HMOX1	hsa3162
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	SLC40A1	KEGG ID N.A.
	Down-regulation	Expression	SLC7A11	hsa23657
	Down-regulation	Expression	SNAI1	hsa6615
	Down-regulation	Expression	SNAI2	hsa6591
	Up-regulation	Expression	TF	KEGG ID N.A.
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
	LoVo	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0399
In Vivo Model	HCT116-luc cells were digested and washed by cold PBS for three times, and the final concentration was 2.5×10⁶/ml in cold PBS. A volume of 100 μl cell suspension was injected subcutaneously into right dorsal flank of mice.
Result	natural product β-elemene is a new ferroptosis inducer and combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroptosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations.